Nuevolution to present at upcoming investor conferences
Stockholm, 8 November 2016. Nuevolution AB (publ) (NUE.ST), a leading small molecule drug discovery biotech company, today announced that it will be presenting at investor conferences in Gothenburg and London on 14 and 18 November 2016, respectively.
PRESENTATION AND WEBCAST ON 14 NOVEMBER, GOTHENBURG
At Aktiespararna’s Stora Aktiedagen 2016 in Gothenburg, Alex Haahr Gouliaev, CEO of Nuevolution AB (publ), will provide an overview of the Company’s business during the live presentation on Monday 14 November 2016, at 16:00-16:30 CET. This event is webcast on http://www.aktiespararna.se/live.
As from 16 November 2016, a replay of this event will be available on http://www.aktiespararna.se/ondemand
PRESENTATION ON 18 NOVEMBER, LONDON
Nuevolution will be presenting at the Biotech and Money Inv€$tival Showcase, a conference which takes place on November 18, 2016 at the Waldorf Hilton Hotel London.
Alex Haahr Gouliaev, CEO, will provide an overview of the Company’s business during the presentation on Friday 18 November 2016 at 12:30 GMT (13:30 CET). Dr. Gouliaev and Mr. Henrik D. Simonsen, the company’s CFO, will be available to participate in one-on-one meetings with investors.
Any investor attending the conference who wish to meet with Nuevolution’s management for a one-on-one meeting should contact Henrik D. Simonsen at firstname.lastname@example.org or Anna Baran-Djokovic at email@example.com.
A replay of the presentation will be available on the investor relations section of Nuevolution’s website, www.nuevolution.com, within a week following the presentation date.
For more information, please contact:
Henrik D. Simonsen, CFO
Phone: +45 3913 0947
Anna Baran-Djokovic, Investor Relations Manager
Phone: +44 7521 083006
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act. The information was sent for publication on Tuesday 8 November 2016, 08:30 (CET).
Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com